Learn how gefapixant, a first-in-class P2X3 receptor antagonist, targets cough hypersensitivity to reduce chronic refractory cough, improve quality of life, and offer an alternative to off‑label neuromodulators.
Learn what retatrutide is, how this next‑generation triple agonist (GLP‑1, GIP, and glucagon) works for weight loss, obesity, and metabolic health, and see key phase 2 clinical trial results on body‑weight reduction and cardiometabolic benefits.
Learn what ensifentrine is, how its dual PDE3/4 inhibition works, and why it’s an emerging inhaled treatment option for COPD. Review its bronchodilatory and anti-inflammatory effects, phase 2b and phase 3 clinical trial results, and impact on lung function, symptoms, and exacerbations.
Discover how zuranolone (SAGE-217), a first-in-class oral neuroactive steroid, offers rapid relief for major depressive disorder and postpartum depression through short 14-day treatment cycles and a novel GABAA receptor mechanism, reshaping options for treatment-resistant depression.
Learn what marituglutide is, how its dual GLP-1/GIP “twincretin” mechanism works, and how it may outperform semaglutide for weight loss, glycemic control, and metabolic health in obesity and type 2 diabetes.
Learn what zuranolone is, how this first-in-class oral neuroactive steroid works on GABA-A receptors, and why it’s generating buzz as a rapid-acting treatment option for major depressive disorder (MDD) and postpartum depression (PPD).
Discover how mirdametinib, a next-generation MEK1/2 inhibitor originally developed for MAPK-driven tumors, is emerging as a promising tool to modulate ERK signaling, improve synaptic plasticity, and potentially treat treatment-resistant depression beyond traditional monoamine-based antidepressants.
Discover what Novelmab is, how its dual targeting of PD‑1 and a tumor‑associated antigen works, and why this next‑generation bispecific antibody is generating buzz in oncology for potentially overcoming resistance to standard immunotherapy in solid tumors.
Learn what tirzepatide is, how its dual GIP and GLP‑1 receptor agonism works, and why clinical trials show unprecedented benefits for blood sugar control and weight loss in type 2 diabetes.
Discover how Nirmatrelvir‑X, an AI‑designed 3CL protease inhibitor, uses generative models, resistance-aware design, and multi‑objective optimization to stay ahead of SARS‑CoV‑2 variants and future coronavirus threats.